(Q37658764)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Potential of ErbB4 antibodies for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Klaus Elenius

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Maija Hollmén

series ordinal

1

1 reference

21 August 2017

Klaus Elenius

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

37-53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20021208%20AND%20SRC:MED&resulttype=core&format=json

ErbB receptors: new insights on mechanisms and biology

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The epidermal growth factor receptor family: biology driving targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

c-erbB-4/HER4: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Role of ErbB4 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocyt

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Analysis of ErbB receptors in pulmonary carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Signaling through ERBB receptors: multiple layers of diversity and control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Novel human antibody therapeutics: the age of the Umabs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Interaction of antibodies with ErbB receptor extracellular regions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Signal transduction. RIPping tyrosine kinase receptors apart

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

c-erbB-4 protein expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Wwox and Ap2gamma expression levels predict tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Prognostic value of ERBB family mRNA expression in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Association of Wwox with ErbB4 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Gene expression profiling of ErbB receptors and ligands in human meningiomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Nuclear and cytoplasmic expression of ErbB-4 in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Somatic mutations of the ERBB4 kinase domain in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Clinical utility of type 1 growth factor receptor expression in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

ERBB receptors in developing, dysplastic and malignant oral epithelia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144

Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.144